

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11694 A2

- (51) International Patent Classification⁷: **A61K 9/00**
- (21) International Application Number: PCT/EP01/08978
- (22) International Filing Date: 2 August 2001 (02.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
100 38 571.0 3 August 2000 (03.08.2000) DE
- (71) Applicant (*for all designated States except US*): **KNOLL GMBH** [DE/DE]; Knollstrasse, 67061 Ludwigshafen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ROSENBERG, Jörg** [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). **BERNDL, Gunther** [DE/DE]; Am Dörrling 7, 67273 Herxheim (DE). **NEUMANN, Jörg** [DE/DE]; Paul-Münch-Strasse 12, 67117 Limburgerhof (DE). **BREITENBACH, Jörg** [DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).
- (74) Agents: **KINZEBACH, Werner** et al.; Reitstötter, Kinzebach & Partner, Sternwartstrasse 4, 81679 München (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/11694 A2

(54) Title: COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN THE ORAL CAVITY IN THE TREATMENT OF MYKOSES

(57) Abstract: A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.

Compositions and dosage forms for application in the oral cavity in the treatment of mykoses

5 The present invention relates to solid pharmaceutical dosage forms for application in the oral cavity, comprising a formulation of an antimycotic active ingredient in the form of a solid dispersion of the active ingredient in a pharmaceutically acceptable matrix.

10

The invention also relates to the use of such formulations for manufacture of a medicament for application in the oral cavity in the treatment of mycoses, especially mycosis caused by *Candida albicans*.

15

Furthermore the invention relates to a process for the manufacture of such formulations.

Since administration of drugs in all regions from the neck up
20 avoids first-pass metabolism, administration in the oral cavity seems to be a very efficacious way to deliver systemic drugs.

This is especially important in the case of pharmaceutically active ingredients which show poor bioavailability due to first
25 pass metabolism and/or poor water-solubility.

In the treatment of oral mykoses it is particularly advantageous to provide for relatively high local concentrations of the active ingredient in the oral cavity.

30

Itraconazol, (\pm)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one, and its pharmaceutically acceptable salts, is known as
35 an effective active ingredient for oral, parenteral and topic treatment of various types of mykoses. Predominantly, itraconazol is administered orally because of its tendency of extensive tissue distribution.

40 However, since itraconazole is almost insoluble in water (less than 1 $\mu\text{g/ml}$), bioavailability is a major problem.

Many attempts have been made to improve the bioavailability of almost insoluble drug compounds. Among them, solid dispersions of
45 drug and hydrophilic polymers have been suggested to enhance the solubility of the drug.

2

WO 97/44014 discloses particles, comprising formulations of itraconazole and water-soluble polymers, said formulations being obtained by melt-extrusion, preferably using hydroxypropyl methylcelluloses as water-soluble polymers. The oral dosage forms disclosed in that document show a remarkably lower food effect.

According to WO 95/31178 mucoadhesive emulsion formulations, comprising itraconazole and cyclodextrins, are useful in the treatment of vaginal infections.

10

The object of the present invention is to provide formulations and dosage forms for application in the oral cavity for the treatment of mykoses, especially mykoses of the oral cavity.

15 Formulations according to the present invention comprise an antimycotic active ingredient in the form of solid dispersions of the active ingredient in a pharmaceutically acceptable matrix, particularly molecular dispersions of the active ingredient in the polymer.

20

Antimycotic active ingredients are preferably compounds with a solubility in water (according to the United States Pharmacopeia XXIII) such that more than 1000 parts of solvent, more preferably more than 10.000 parts of solvent are needed for one part of

25

solute.

A preferred active ingredient is the above-identified itraconazole. Other suitable active ingredients are saperconazole, ketoconazole or fluconazole.

30

One preferred embodiment of the invention relates to lozenges.

Another preferred embodiment of the invention relates to solid dosage forms comprising mucoadhesive polymers, preferably tablets for sublingual or buccal application. Tablets for gingival or palatal application are also within the scope of the invention.

35

According to the present invention the active ingredient is homogeneously dispersed in a pharmaceutically acceptable matrix.

40 Preferably, the solid dispersion is in the form of a molecular dispersion of the active ingredient, i.e. a so-called "solid solution". The term "solid solution" is familiar to the skilled person.

45

3

The pharmaceutically acceptable matrix is based on polymers or low-molecular excipients normally used as fillers for tableting such as for instance sugars or sugar alcohols as matrix building components.

5

Suitable polymers are selected from the group consisting of:

Cellulose derivatives, e.g. alkylcelluloses,
hydroxyalkylcelluloses, hydroxyalkyl alkylcelluloses.

10

Acrylic polymers of the Eudragit® type like copolymers based on methacrylic acid and methacrylic acid methyl ester

Homo- and copolymers of N-vinylpyrrolidone with Fikentscher K

15 values in the range of from 17 to 100, vinylacetate being a preferred comonomer, e.g. a copolymer obtained from 60 % b.w. of n-vinylpyrrolidone and 40 % b.w. of vinyl acetate

Polyethylene glycols with molecular weights in the range of from
20 6000 to 100.000 Dalton, polyoxyethylene polyoxypropylene block copolymers

Suitable low-molecular weight matrix components are selected from the group consisting of sugars and sugar alcohols, for example
25 sorbitol, xylitol, maltitol, erythritol, mannitol, isomalt and the like.

In the case of formulations for lozenges sugar alcohols are preferred matrix components.

30

The amount of matrix building components used in the formulations may range from 5 to 90 % b.w., preferably 10 to 70 % b.w., more preferably 10 to 50 % b.w..

35 Notwithstanding the fact that some of the aforementioned matrix building polymers show mucoadhesive properties, such polymers are only used optionally in formulations for lozenges. However, formulations or finished dosage forms for buccal, sublingual, gingival or palatinal application preferably comprise such
40 mucoadhesive polymers, optionally in combination with other polymers. Such mucoadhesive polymers are selected from the group consisting of:

Acrylic copolymers of the Eudragit® type

45 Crosslinked polyacrylics (CTFA name: Carbomer)

Sodium carboxymethylcellulose

Tragant gum

Poly(methyl)vinylether-co- maleic acid anhydride
Alkylcelluloses, e.g. methylcellulose
Alginates like sodium alginate
Polyvinylpyrrolidone

5

According to one embodiment of the invention the mucoadhesive polymer is incorporated in the melt formulation.

According to another embodiment of the invention the solid
10 dispersions of the active ingredient obtained by melt formulation are mixed with one or more mucoadhesive polymers and subsequently processed to finished dosage forms (tablets). For example, 10 to 70 % b.w. of a solid dispersion of the active ingredient in a pharmaceutically acceptable matrix as outlined above can be mixed
15 with 30 to 90 % b.w. of mucoadhesive polymers.

In addition the matrix formulations or finished dosage forms may contain conventional pharmaceutical ancillary substances, for example extenders such as silicates or diatomaceous earth, mould
20 releasers such as stearic acid or salts thereof, wetting agents, preservatives, disintegrants, absorbants, colorants, and the like (cf., for example H. Sucker et al. Pharmazeutische Technologie, Thieme Verlag, Stuttgart 1978). The ancillary substances must be thermally stable at the temperature used in the process for
25 manufacture used here.

Preferred ancillary substances are flavourings and artificial sweeteners for masking the sometimes unpleasant taste of the drug compounds. Suitable artificial sweeteners are for instance sodium
30 saccharinate, aspartame, neohesperidine or acesulfame, preferably acesulfame or mixtures comprising acesulfame and aspartame. These sweeteners are used in amounts of from 0.05 to 1.0 % b.w., preferably 0.2 to 0.5 to 0.5 b.w.. Another preferred class of sweeteners are sugar alcohols, preferably xylitol, maltitol or
35 isomalt. In case sugar alcohols are used as matrix components additional sweeteners normally are not needed. Sugar alcohols can be used in amounts of from 2 to 60 % b.w., preferably 5 to 40 % b.w..

40 A preferred method for manufacturing the formulations and finished dosage forms of the present invention is a melt-extrusion process. A preferred apparatus for such process is an extruder equipped with one or more screws, preferably a twin screw extruder. The mixtures comprising all the components of the
45 pharmaceutical formulations can be processed at temperatures in the range of from 50 to 180°C, preferably 80 to 160°C. Preferably

the process is carried out in the absence of solvents, e.g. water or organic solvents.

In addition, small amounts of crosslinked polyvinylpyrrolidone 5 (Kollidon® CL) can be used as taste masking agent.

The molten pharmaceutical mixtures are extruded and the still thermoplastic mass is subsequently shaped. Shaping can take place e.g. by hot cutting the extruded strands to give granules or 10 pellets which can be pressed to tablets in a conventional way.

A preferred method for shaping is a calendering process as described for instance in EP-A 240 906 which comprises that the still deformable extrudate is fed between the surfaces of two 15 counter-rotating molding rolls, the surfaces of said rolls having opposed depressions, whereby, separate tablets having the shape of such depressions are formed. The calender and molding rolls useful for the present invention can be cooled or heated per se and the optimum surface temperature of the rolls for the relevant 20 processing step can be adjusted in this way.

The invention also relates to specifically shaped dosage forms for those formulations comprising mucoadhesive polymers.

25 Preferred dosage forms are lenticular or semi-lenticular tablets which can be round or oval and with an angle α (see Fig.) between the cross-sectional plane of the tablet and the convex tablet body (tangential area) of less than 90° . Fig. 1 and 2 show such an oval lenticular tablet with a tablet length (a), tablet width (b) 30 and thickness (c). Fig. 3 and 4 show a round lenticular tablet with a diameter (d) and a thickness (c).

For instance, oval lozenges can have a length of from 10 to 20 mm, a width of from 6 to 12 mm and a thickness of from 3 to 35 12 mm. Round lozenges can have a diameter of from 5 to 14 mm and a thickness of from 3 to 10 mm.

In the case of semi-lenticular tablets the lower half of the tablet is essentially planar. Fig. 5 shows a round 40 semi-lenticular tablet, Fig. 6 an oval semi-lenticular tablet. Such tablet forms are especially well suited for buccal, gingival, sublingual or palatal application, since they cause little irritation when positioned in the oral cavity. Also, in view of the low tablet weight generally accepted for buccal forms 45 (up to 200 mg per tablet) the ratio of surface to tablet volume is particularly advantageous because of the large surface. Such tablets can have a length of from 3 to 10 mm, a width of from 2

6

to 6 mm, a thickness of from 1.5 to 5 mm (oval forms) or a diameter of from 3 to 10 mm and a thickness of from 1.5 to 5 mm (round forms). Round semi-lenticular tablets are preferred.

5 Such dosage forms can be manufactured using a calendering process as described above. In the case of semi-lenticular tablets only one of the calender rolls is having depressions, whereas the other roll is planar.

10 Another method for manufacturing semi-lenticular tablets is by shaping the melt with the aid of a rotating perforated roll into drops which are subsequently solidified by cooling.

The dosage forms obtained according to the present invention are
15 particularly useful in the treatment of oral mykoses.

Surprisingly, the solid solutions according to the present invention deliver the active ingredient without substantial recrystallization in an aqueous environment like the oral cavity,
20 thus achieving sufficient plasma levels.

Therefore, the dosage forms according to the invention are useful in the treatment of diseases of the oral cavity by delivering high local concentrations as well as in systemic treatment.

25

Examples

General Method

30 Tablets were produced starting from molten mixtures of the components and extruding said mixtures using a twin screw extruder (Leistritz Micro 18). The still thermoplastic extrudate was calendered as described in EP-A 240 906 to give oval lozenges of 17,4 mm length, 8.5 mm width and 4.7 mm thickness with a mean
35 tablet weight of 450 mg.

The dissolution rates were determined according to the USP-paddle model at 50 rpm. 37°C, no change pH 1.0 (0.5 % SDS).

40 The formation of solid solutions was determined by DSC (Differential Scanning Calorimetry) measurements using a Mettler TA 4000 System.

45

Example 1

Itraconazol	20 % b.w.
Hydroxypropylcellulose	80 % b.w.
5 Melt temperature:	133°C
Dissolution: 95 % after 8 h	

Example 2

10 Itraconazol	20 % b.w.
Hydroxypropylcellulose	70 % b.w.
Hydroxypropylmethylcellulose	10 % b.w.
Melt temperature:	135°C
Dissolution: 77 % after 8 h	

15

Example 3

Itraconazol	20 % b.w.
N-vinylpyrrolidone vinylacetate	
20 Copolymer (VP/Vac 60/40)	60 % b.w.
Hydroxypropylcellulose	10 % b.w.
Melt temperature:	152°C
Dissolution: 93 % after 8 h	

25

30

35

40

45

Claims

1. A solid dosage form for application in the oral cavity,
5 comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.
2. A dosage form according to claim 1, wherein the active ingredient is molecularly dispersed in the matrix.
- 10 3. A dosage form according to claims 1 or 2, wherein the solubility of the pharmaceutically active ingredient in water is such that more than 10.000 parts of water are needed for one part of active ingredient.
- 15 4. A dosage form according to any of claims 1 to 3, comprising itraconazole as active ingredient.
5. A dosage form according to any of the claims 1 to 4 in the
20 form of a lozenge.
6. A dosage form according to claim 5 comprising one or more sugar alcohols as matrix components.
- 25 7. A dosage form according to any of the claims 1 to 4, comprising mucoadhesive polymers.
8. A dosage form according to claim 7, wherein the mucoadhesive polymer is a crosslinked polyacrylic acid.
- 30 9. A dosage form according to claim 7, wherein the mucoadhesive polymer is a poly(meth)acrylate.
10. A dosage form according to any of the claims 7 to 9 in
35 the form of a tablet for buccal, sublingual, gingival or palatal application.
11. A dosage form according to claim 10, consisting of lenticular or semi-lenticular shaped tablets.
- 40 12. A dosage form according to any of claims 1 to 11, obtained by a melt-extrusion process.

13. The use of dosage forms according to any of claims 1 to 12 for the manufacture of a medicament for the treatment of mykoses.

5 14. The use according to claim 13 for the manufacture of a medicament for the treatment of oral mykoses.

10

15

20

25



30

35



40

45


1 / 4

*Fig. 1**Fig. 2*


2 / 4

*Fig. 3**Fig. 4*

3 / 4

*Fig. 5*

4 / 4

*Fig. 6*

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/11694 A3

(51) International Patent Classification⁷: **A61K 9/20**,
A61P 31/10

(21) International Application Number: PCT/EP01/08978

(22) International Filing Date: 2 August 2001 (02.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
100 38 571.0 3 August 2000 (03.08.2000) DE

(71) Applicant (for all designated States except US): **KNOLL GMBH** [DE/DE]; Knollstrasse, 67061 Ludwigshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSENBERG, Jörg** [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). **BERNDL, Gunther** [DE/DE]; Am Dörrling 7, 67273 Herxheim (DE). **NEUMANN, Jörg** [DE/DE]; Paul-Münch-Strasse 12, 67117 Limburgerhof (DE). **BREITENBACH, Jörg** [DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).

(74) Agents: **KINZEBACH, Werner** et al.; Reitstötter, Kinzebach & Partner, Sternwartstrasse 4, 81679 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
25 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN THE ORAL CAVITY IN THE TREATMENT OF MYKOSES

(57) Abstract: A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.

WO 02/11694 A3



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/08978

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/20 A61P31/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 578 315 A (CHIEN YIE W ET AL) 26 November 1996 (1996-11-26) column 1, line 51 -column 2, line 29 column 6, line 3 column 6, line 67 -column 7, line 4 example 2 claim 1 ---	1-5,7,8, 10,11, 13,14
X	EP 0 250 187 A (JOHNSON & JOHNSON PROD INC) 23 December 1987 (1987-12-23) page 3, line 1 - line 17 page 4, line 4 example 3 claim 1 --- -/--	1-3,7, 12-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

22 February 2002

Date of mailing of the international search report

01/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08978

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 431 915 A (HARVEY BRYCE M ET AL) 11 July 1995 (1995-07-11) column 3, line 14 - line 28 column 4, line 66 - column 5, line 12 column 8, line 52 - line 61 claims 1,18,19 ----	1-3, 12-14
X	WO 97 44014 A (JANSSEN PHARMACEUTICA NV) 27 November 1997 (1997-11-27) cited in the application page 3, line 29 - page 5, line 2 page 6, line 30 - page 7, line 16 page 12, line 22 - line 36 page 14, line 11 - line 13 example 1 claims 1,6 ----	1-14
X	WO 93 18757 A (PFIZER) 30 September 1993 (1993-09-30) example 2 ----	1-3,5,7, 10,11,13
X	EP 0 864 326 A (KNOLL AG) 16 September 1998 (1998-09-16) column 5, line 45,54 column 8, line 3 - line 13 example 1 ----	1-3,5,7, 10-12
A	DE 195 39 359 A (KNOLL AG) 24 April 1997 (1997-04-24) column 1, line 56 - line 67 column 4, line 37 - line 47 column 5, line 22 - line 43 column 7, line 38,47 figure 2 ----	1-14
A	EP 0 240 906 A (BASF AG) 14 October 1987 (1987-10-14) cited in the application page 4, line 15 page 1, line 12 - line 21 page 3, line 1 - line 17 -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08978

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5578315	A	26-11-1996	AU 1100295 A	19-06-1995
			EP 0731679 A1	18-09-1996
			JP 9506092 T	17-06-1997
			WO 9515137 A1	08-06-1995
EP 0250187	A	23-12-1987	US 4713243 A	15-12-1987
			AT 95058 T	15-10-1993
			AU 7415587 A	17-12-1987
			CA 1297408 A1	17-03-1992
			DE 3787573 D1	04-11-1993
			DE 3787573 T2	10-02-1994
			EP 0250187 A2	23-12-1987
			GR 870935 A1	19-10-1987
			IE 61785 B	30-11-1994
			JP 2706064 B2	28-01-1998
			JP 8253414 A	01-10-1996
			JP 2540332 B2	02-10-1996
			JP 63019152 A	26-01-1988
			KR 9411243 B1	03-12-1994
			NZ 220573 A	28-11-1989
			PH 24845 A	30-10-1990
			SG 107694 G	28-10-1994
			US RE33093 E	17-10-1989
			ZA 8704294 A	25-01-1989
US 5431915	A	11-07-1995	NONE	
WO 9744014	A	27-11-1997	AU 722101 B2	20-07-2000
			AU 2956297 A	09-12-1997
			BG 102532 A	26-02-1999
			BR 9706897 A	31-08-1999
			CA 2240161 A1	27-11-1997
			CN 1209740 A	03-03-1999
			CZ 9801885 A3	11-11-1998
			EE 9800304 A	15-02-1999
			WO 9744014 A1	27-11-1997
			EP 0904060 A1	31-03-1999
			HR 970270 A1	30-04-1998
			HU 9901620 A2	28-10-1999
			JP 11509238 T	17-08-1999
			NO 982599 A	19-11-1998
			NZ 330739 A	29-06-1999
			PL 330931 A1	07-06-1999
			SK 84898 A3	10-03-1999
			TR 9801225 T2	23-11-1998
			US 2001007678 A1	12-07-2001
			ZA 9704338 A	19-11-1998
WO 9318757	A	30-09-1993	AT 140625 T	15-08-1996
			AU 3057592 A	21-10-1993
			BR 9207104 A	05-12-1995
			CA 2131089 A1	18-09-1993
			CZ 9402258 A3	18-01-1995
			DE 69212503 D1	29-08-1996
			DE 69212503 T2	12-12-1996
			DK 630237 T3	26-08-1996
			EP 0630237 A1	28-12-1994
			ES 2089581 T3	01-10-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08978

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9318757	A	FI 944309 A GR 3020666 T3 HU 75616 A2 IL 105016 A JP 2559206 B2 JP 7501829 T MX 9301435 A1 NO 943461 A NZ 247168 A WO 9318757 A1 US 5529789 A ZA 9301858 A	16-09-1994 31-10-1996 28-05-1997 12-09-1996 04-12-1996 23-02-1995 01-10-1993 16-09-1994 28-03-1995 30-09-1993 25-06-1996 16-09-1994
EP 0864326	A 16-09-1998	DE 19710009 A1 CA 2229650 A1 EP 0864326 A2 JP 10310518 A	24-09-1998 12-09-1998 16-09-1998 24-11-1998
DE 19539359	A 24-04-1997	DE 19539359 A1 AU 705657 B2 AU 7491196 A BR 9611239 A CA 2232353 A1 CN 1200663 A CZ 9801096 A3 WO 9715268 A1 EP 0957884 A1 HU 9900734 A2 JP 11514275 T NO 981795 A SI 9620112 A SK 50698 A3 ZA 9608848 A	24-04-1997 27-05-1999 15-05-1997 30-03-1999 01-05-1997 02-12-1998 14-07-1999 01-05-1997 24-11-1999 28-10-1999 07-12-1999 23-04-1998 31-08-1998 11-01-1999 22-04-1998
EP 0240906	A 14-10-1987	DE 3612211 A1 AT 63056 T AU 590697 B2 AU 7140087 A CA 1303501 A1 CN 87102755 A ,B CS 8702531 A2 DE 3769687 D1 EP 0240906 A2 FI 871538 A ,B, GR 3002559 T3 HR 931378 A1 HU 55218 A2 JP 1977258 C JP 7008293 B JP 62240061 A KR 9405302 B1 NO 173588 C PT 84660 A ,B SI 8710590 A8 US 4880585 A YU 59087 A1	15-10-1987 15-05-1991 09-11-1989 15-10-1987 16-06-1992 28-10-1987 13-10-1989 06-06-1991 14-10-1987 12-10-1987 25-01-1993 30-04-1996 28-05-1991 17-10-1995 01-02-1995 20-10-1987 16-06-1994 05-01-1994 01-05-1987 31-08-1996 14-11-1989 31-12-1989